REDWOOD CITY, Calif.
Sept. 15, 2011
/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that
, President and Chief Executive Officer, will present at two separate investor conferences in
New York City
over the coming weeks as follows:
UBS Global Life Sciences Conference
Date: Tuesday, September 20th at
7:30 AM EST
Location: Grand Hyatt New York
The Sixth Annual JMP Securities Healthcare Conference
Date: Wednesday, September 28th at
11:00 AM EST
Location: The St. Regis New York
Both presentations will be webcast live and can be accessed through the links above. For those not available to listen to the live broadcast, the presentations will be archived and available through
About AcelRx Pharmaceuticals, Inc.
Redwood City, CA
, AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab PCA System, which is in preparation for Phase 3 clinical development, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. AcelRx has two additional product candidates which have completed Phase 2 clinical development: ARX-02 for the treatment of cancer breakthrough pain, and ARX-03 for providing mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. A fourth product candidate, ARX-04, is a sufentanil product for the treatment of moderate-to-severe acute pain that is expected to enter Phase 2 clinical development in the second half of 2011 under a grant from the US Army Medical Research and Material Command.
SOURCE AcelRx Pharmaceuticals, Inc.